Get Premium to unlock powerful stock data

Octagon Capital Advisors LP Buys Arcus Biosciences Inc, ITeos Therapeutics Inc, Apellis Pharmaceuticals Inc, Sells Curis Inc, IVERIC bio Inc, NGM Biopharmaceuticals Inc

Author's Avatar
Feb 19, 2022
Article's Main Image
Investment company Octagon Capital Advisors LP (Current Portfolio) buys Arcus Biosciences Inc, ITeos Therapeutics Inc, Apellis Pharmaceuticals Inc, BridgeBio Pharma Inc, Keros Therapeutics Inc, sells Curis Inc, IVERIC bio Inc, NGM Biopharmaceuticals Inc, Omega Therapeutics Inc, Ikena Oncology Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Octagon Capital Advisors LP. As of 2021Q4, Octagon Capital Advisors LP owns 28 stocks with a total value of $514 million. These are the details of the buys and sells.

For the details of Octagon Capital Advisors LP's stock buys and sells, go to https://www.gurufocus.com/guru/octagon+capital+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of Octagon Capital Advisors LP
  1. Apellis Pharmaceuticals Inc (APLS) - 2,020,911 shares, 18.59% of the total portfolio. Shares added by 26.63%
  2. Arcus Biosciences Inc (RCUS) - 2,095,231 shares, 16.50% of the total portfolio. Shares added by 115.97%
  3. I-MAB (IMAB) - 1,049,691 shares, 9.68% of the total portfolio. Shares added by 37.31%
  4. 4D Molecular Therapeutics Inc (FDMT) - 1,551,070 shares, 6.62% of the total portfolio. Shares added by 86.59%
  5. BridgeBio Pharma Inc (BBIO) - 1,767,486 shares, 5.74% of the total portfolio. Shares added by 210.40%
New Purchase: ITeos Therapeutics Inc (ITOS)

Octagon Capital Advisors LP initiated holding in ITeos Therapeutics Inc. The purchase prices were between $26.23 and $47.86, with an estimated average price of $33.65. The stock is now traded at around $33.830000. The impact to a portfolio due to this purchase was 4.08%. The holding were 450,776 shares as of 2021-12-31.

New Purchase: Keros Therapeutics Inc (KROS)

Octagon Capital Advisors LP initiated holding in Keros Therapeutics Inc. The purchase prices were between $36.95 and $62.89, with an estimated average price of $50.29. The stock is now traded at around $52.090000. The impact to a portfolio due to this purchase was 3.87%. The holding were 340,214 shares as of 2021-12-31.

New Purchase: Chinook Therapeutics Inc (KDNY)

Octagon Capital Advisors LP initiated holding in Chinook Therapeutics Inc. The purchase prices were between $10.69 and $16.83, with an estimated average price of $14.32. The stock is now traded at around $13.050000. The impact to a portfolio due to this purchase was 1.59%. The holding were 500,000 shares as of 2021-12-31.

New Purchase: Immunovant Inc (IMVT)

Octagon Capital Advisors LP initiated holding in Immunovant Inc. The purchase prices were between $7.33 and $9.32, with an estimated average price of $8.24. The stock is now traded at around $5.490000. The impact to a portfolio due to this purchase was 0.95%. The holding were 572,862 shares as of 2021-12-31.

New Purchase: Olema Pharmaceuticals inc (OLMA)

Octagon Capital Advisors LP initiated holding in Olema Pharmaceuticals inc. The purchase prices were between $8.75 and $30.71, with an estimated average price of $20.45. The stock is now traded at around $4.500000. The impact to a portfolio due to this purchase was 0.42%. The holding were 231,417 shares as of 2021-12-31.

New Purchase: Compass Therapeutics Inc (CMPX)

Octagon Capital Advisors LP initiated holding in Compass Therapeutics Inc. The purchase prices were between $2.88 and $4.08, with an estimated average price of $3.56. The stock is now traded at around $2.400000. The impact to a portfolio due to this purchase was 0.15%. The holding were 240,000 shares as of 2021-12-31.

Added: Arcus Biosciences Inc (RCUS)

Octagon Capital Advisors LP added to a holding in Arcus Biosciences Inc by 115.97%. The purchase prices were between $31.38 and $48.47, with an estimated average price of $39.08. The stock is now traded at around $30.490000. The impact to a portfolio due to this purchase was 8.86%. The holding were 2,095,231 shares as of 2021-12-31.

Added: Apellis Pharmaceuticals Inc (APLS)

Octagon Capital Advisors LP added to a holding in Apellis Pharmaceuticals Inc by 26.63%. The purchase prices were between $30.74 and $49.16, with an estimated average price of $39.7. The stock is now traded at around $42.730000. The impact to a portfolio due to this purchase was 3.91%. The holding were 2,020,911 shares as of 2021-12-31.

Added: BridgeBio Pharma Inc (BBIO)

Octagon Capital Advisors LP added to a holding in BridgeBio Pharma Inc by 210.40%. The purchase prices were between $11.38 and $53.41, with an estimated average price of $42.17. The stock is now traded at around $8.080000. The impact to a portfolio due to this purchase was 3.89%. The holding were 1,767,486 shares as of 2021-12-31.

Added: 4D Molecular Therapeutics Inc (FDMT)

Octagon Capital Advisors LP added to a holding in 4D Molecular Therapeutics Inc by 86.59%. The purchase prices were between $19.56 and $32.94, with an estimated average price of $24.43. The stock is now traded at around $13.970000. The impact to a portfolio due to this purchase was 3.07%. The holding were 1,551,070 shares as of 2021-12-31.

Added: I-MAB (IMAB)

Octagon Capital Advisors LP added to a holding in I-MAB by 37.31%. The purchase prices were between $45.28 and $74.5, with an estimated average price of $59.71. The stock is now traded at around $26.720000. The impact to a portfolio due to this purchase was 2.63%. The holding were 1,049,691 shares as of 2021-12-31.

Added: Stoke Therapeutics Inc (STOK)

Octagon Capital Advisors LP added to a holding in Stoke Therapeutics Inc by 164.05%. The purchase prices were between $18.11 and $30.72, with an estimated average price of $23.85. The stock is now traded at around $18.930000. The impact to a portfolio due to this purchase was 2.27%. The holding were 783,769 shares as of 2021-12-31.

Sold Out: Curis Inc (CRIS)

Octagon Capital Advisors LP sold out a holding in Curis Inc. The sale prices were between $4.45 and $8.09, with an estimated average price of $5.89.

Sold Out: IVERIC bio Inc (ISEE)

Octagon Capital Advisors LP sold out a holding in IVERIC bio Inc. The sale prices were between $13.83 and $18.78, with an estimated average price of $16.39.

Sold Out: NGM Biopharmaceuticals Inc (NGM)

Octagon Capital Advisors LP sold out a holding in NGM Biopharmaceuticals Inc. The sale prices were between $17.26 and $22.02, with an estimated average price of $19.14.

Sold Out: Ikena Oncology Inc (IKNA)

Octagon Capital Advisors LP sold out a holding in Ikena Oncology Inc. The sale prices were between $10.52 and $16.96, with an estimated average price of $13.55.

Sold Out: PMV Pharmaceuticals Inc (PMVP)

Octagon Capital Advisors LP sold out a holding in PMV Pharmaceuticals Inc. The sale prices were between $19.99 and $30.01, with an estimated average price of $24.06.

Sold Out: Edgewise Therapeutics Inc (EWTX)

Octagon Capital Advisors LP sold out a holding in Edgewise Therapeutics Inc. The sale prices were between $14.41 and $22.41, with an estimated average price of $18.02.



Here is the complete portfolio of Octagon Capital Advisors LP. Also check out:

1. Octagon Capital Advisors LP's Undervalued Stocks
2. Octagon Capital Advisors LP's Top Growth Companies, and
3. Octagon Capital Advisors LP's High Yield stocks
4. Stocks that Octagon Capital Advisors LP keeps buying
Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles